Researchers from the National Defense Medical Center in Taiwan have identified an increased risk of psoriasis in patients with cancer undergoing immune checkpoint inhibitor (ICI) treatments, with implications for other immune-related adverse events.

Over the past decade, ICIs have become an increasingly important part of cancer immunotherapy. ICI therapies enhance the immune system’s ability to fight cancer cells but have been associated with adverse events. These events can result from a loss of T-cell tolerance, allowing the immune system to attack healthy organ tissues such as the skin, gastrointestinal tract, liver, lungs, and endocrine system.

Source:

Psoriasis Risk With Immune Checkpoint Inhibitors

https://jamanetwork.com/journals/jamadermatology/article-abstract/2825850